How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study

How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study

Abstract Janus kinase 2 (JAK2) has been regarded as an essential target for the treatment of myeloproliferative neoplasms (MPNs). BBT594 and CHZ868, Type-II inhibitors of JAK2, illustrate satisfactory efficacy in preclinical MPNs and acute lymphoblastic leukemia (ALL) models. However, the L884P muta...

Full description

Bibliographic Details
Main Authors:	Xiaotian Kong, Huiyong Sun, Peichen Pan, Dan Li, Feng Zhu, Shan Chang, Lei Xu, Youyong Li, Tingjun Hou
Format:	Article
Language:	English
Published:	Nature Portfolio 2017-08-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-017-09586-3

Similar Items

P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape.
by: Huiyong Sun, et al.
Published: (2014-07-01)

P884: Withdrawn
Published: (2024-01-01)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
by: Charlotte E. J. Downes, et al.
Published: (2021-08-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

The selective interaction between silica nanoparticles and enzymes from molecular dynamics simulations.
by: Xiaotian Sun, et al.
Published: (2014-01-01)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr.
Published: (2022-09-01)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
by: Ulrike Blume-Peytavi, et al.
Published: (2015-04-01)

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
by: Vibeke Strand
Published: (2021-04-01)

884 Tumor-directed immunoradiotherapy enhances surveillance from the sentinel lymph node
by: Ezra Cohen, et al.
Published: (2023-11-01)

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors
by: Tekla Hornakova, et al.
Published: (2011-06-01)

JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
by: Inge Govaerts, et al.
Published: (2019-12-01)

17.884J / 14.296J Collective Choice I, Fall 2005
by: Snyder, James M.
Published: (2005)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
by: Martina Morelli, et al.
Published: (2018-01-01)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
by: Radoslav Janostiak, et al.
Published: (2019-06-01)

Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review
by: Ji Wen, et al.
Published: (2021-01-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2021-08-01)

A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
by: Sivahari Prasad Gorantla, et al.
Published: (2024-02-01)

Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review
by: Krasimir Kraev, et al.
Published: (2023-11-01)

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma
by: Cristina Pérez, et al.
Published: (2015-11-01)

JAK inhibitors in rheumatology
by: Kunihiro Yamaoka, et al.
Published: (2023-07-01)

JAK inhibitors ∼ overview∼
by: Hideto Kameda
Published: (2023-07-01)

The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders
by: Zhijian Xiao, et al.
Published: (2008-05-01)

A hybrid ensemble learning approach for indoor thermal comfort predictions utilizing the ASHRAE RP-884 database
by: Feng, Xue, et al.
Published: (2023)

Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
by: Taylor, PC, et al.
Published: (2024)

Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary
by: Peter C. Taylor, et al.
Published: (2024-10-01)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
by: Ailin Zhao, et al.
Published: (2023-08-01)

JAK2V617F/TET2 mutations: does the order matter?
by: Elodie Pronier, et al.
Published: (2011-05-01)

Tyrosine kinase mutations of JAK2 are rare events in AML but influence prognosis of patients with CBF-leukemias
by: Thomas Illmer, et al.
Published: (2007-01-01)

A study of temperate climate for comfort temperature predictions in natural ventilation buildings using Ashrae Rp-884 database
by: Tay, Lee Yong
Published: (2019)

Mucosal Epithelial Jak Kinases in Health and Diseases
by: Narendra Kumar, et al.
Published: (2021-01-01)

JAK inhibitors in rheumatoid arthritis
by: Taylor, PC
Published: (2019)

JAK Inhibitors in Rheumatoid Arthritis
by: Kathryn Biddle, et al.
Published: (2022-08-01)

JAK Inhibitors in Psoriatic Disease
by: Megna M, et al.
Published: (2023-10-01)

JAK inhibitors and COVID-19
by: Gabriel Levy, et al.
Published: (2022-04-01)

A Comprehensive Overview of Globally Approved JAK Inhibitors
by: Ahmed M. Shawky, et al.
Published: (2022-05-01)

Structural stability and O2 dissociation on nitrogen-doped graphene with transition metal atoms embedded: A first-principles study
by: Mingye Yang, et al.
Published: (2015-06-01)

The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220
by: Daphnie Pauwels, et al.
Published: (2012-11-01)

Predicting the mutation effects of protein–ligand interactions via end-point binding free energy calculations: strategies and analyses
by: Yang Yu, et al.
Published: (2022-08-01)

Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
by: Stevan R. Hubbard
Published: (2018-01-01)

Computational Screening and Experimental Validation on Multicomponent Crystals of a New Class of Janus Kinase (JAK) Inhibitor Drug with Improved Solubility
by: Yujiang Xie, et al.
Published: (2022-11-01)